Literature DB >> 20538374

Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo.

Taher Darreh-Shori1, Anton Forsberg, Negar Modiri, Niels Andreasen, Kaj Blennow, Chelenk Kamil, Hiba Ahmed, Ove Almkvist, Bengt Långström, Agneta Nordberg.   

Abstract

Recently, we reported that 3 of the known risk factors of Alzheimer's disease (AD), i.e., advanced age, apolipoprotein E (ApoE) ε4, and female gender, are associated with differential levels of ApoE proteins and butyrylcholinesterase (BuChE) in the cerebrospinal fluid (CSF) of AD patients. The ApoE ε4 allele and certain BuChE polymorphisms synergistically affect the conversion rate of mild cognitive impairment (MCI) to AD. Here, we investigated interrelationships between ApoE and BuChE levels, and pathological markers of AD in vivo. CSF from patients with probable AD, assessed for cerebral glucose metabolism (CMRglc; n = 50) and Pittsburgh compound B (PIB) retention (β-amyloid [Aβ] load, n = 29) by positron emission tomography (PET), was used for measurement of BuChE, ApoE, Aβ, tau, phosphorylated tau (P-tau) and interleukin-1β (IL-1β) levels. Levels of ApoE and BuChE strongly correlated with CMRglc (fluorodeoxyglucose [FDG]-PET, r = 0.54, p < 0.0001, n = 50), cerebral Aβ load (PIB retention, r = 0.73, p < 0.0001, n = 29), and CSF P-tau (r = 0.73, p < 0.0001, n = 33). High ApoE protein was tied to low CMRglc and high PIB retention and P-tau. BuChE levels had opposite relationships. Other CSF covariates were levels of interleukin-1β and Aβ(42) peptide. The pattern of the patients' cognitive Z-scores strongly supported these observations. High ApoE protein was also linked to changes in 3 of the biodynamic properties of BuChE. In vitro analysis indicated that high ApoE protein levels were related to an increased pool of dormant BuChE molecules with an abnormally high intrinsic catalytic rate in CSF, which was "turned on" by excess Aβ peptides. The findings suggest that abnormally high levels of ApoE may play a causative role in the pathological events of AD, particularly those involving the early cholinergic deficit in the AD brain, through modulation of cholinesterases activities, hence disturbing the acetylcholine-dependent activity of neurons and nonexcitable cells such as glial cells.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538374     DOI: 10.1016/j.neurobiolaging.2010.04.028

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  26 in total

Review 1.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.

Authors:  William E Klunk
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  PET radiopharmaceuticals for probing enzymes in the brain.

Authors:  Jason P Holland; Paul Cumming; Neil Vasdev
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-04-09

3.  Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis.

Authors:  Jungsu Kim; Hong Jiang; Seonha Park; Adam E M Eltorai; Floy R Stewart; Hyejin Yoon; Jacob M Basak; Mary Beth Finn; David M Holtzman
Journal:  J Neurosci       Date:  2011-12-07       Impact factor: 6.167

Review 4.  Cholinergic modulation of the hippocampal region and memory function.

Authors:  Juhee Haam; Jerrel L Yakel
Journal:  J Neurochem       Date:  2017-08       Impact factor: 5.372

5.  Isotopic N,N-dimethyl leucine tags for absolute quantification of clusterin and apolipoprotein E in Alzheimer's disease.

Authors:  Yuan Liu; Hua Zhang; Xiaofang Zhong; Zihui Li; Henrik Zetterberg; Lingjun Li
Journal:  J Proteomics       Date:  2022-02-03       Impact factor: 4.044

Review 6.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

7.  Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load.

Authors:  Adi Alkalay; Gil D Rabinovici; Gabriel Zimmerman; Neha Agarwal; Daniela Kaufer; Bruce L Miller; William J Jagust; Hermona Soreq
Journal:  Curr Alzheimer Res       Date:  2013-01       Impact factor: 3.498

8.  The synergistic risk effect of apolipoprotein ε4 and DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B) haplotype for Alzheimer's disease.

Authors:  Cíntia Monique Boschmann Ens de Bem; Julio Carlos Pezzi; Ericksen Mielle Borba; Marcia Lorena Fagundes Chaves; Fabiana Michelsen de Andrade; Marilu Fiegenbaum; Analuiza Camozzato
Journal:  Mol Biol Rep       Date:  2016-05-17       Impact factor: 2.316

9.  A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Authors:  Agneta Nordberg; Clive Ballard; Roger Bullock; Taher Darreh-Shori; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-07

Review 10.  The diabetic brain and cognition.

Authors:  Peter Riederer; Amos D Korczyn; Sameh S Ali; Ovidiu Bajenaru; Mun Seong Choi; Michael Chopp; Vesna Dermanovic-Dobrota; Edna Grünblatt; Kurt A Jellinger; Mohammad Amjad Kamal; Warda Kamal; Jerzy Leszek; Tanja Maria Sheldrick-Michel; Gohar Mushtaq; Bernard Meglic; Rachel Natovich; Zvezdan Pirtosek; Martin Rakusa; Melita Salkovic-Petrisic; Reinhold Schmidt; Angelika Schmitt; G Ramachandra Sridhar; László Vécsei; Zyta Beata Wojszel; Hakan Yaman; Zheng G Zhang; Tali Cukierman-Yaffe
Journal:  J Neural Transm (Vienna)       Date:  2017-08-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.